Remembering Gustave Eisemann, Cigall Kadoch Wins 2019 Wachtel Cancer Research Prize, and more

Gustave Eisemann, MD

Remembering Gustave Eisemann (1926 – 2019)

Gustave Eisemann, MD, passed away on May 26, 2019.

Born in Halberstadt, Germany, Dr. Eisemann came to the U.S. in 1938, settling in Kansas City, Kansas. He graduated from the University of Kansas School of Medicine in 1948, then served as a captain and flight surgeon in the U.S. Air Force from 1949 to 1951 before completing his hematology fellowship at the New England Medical Center in Boston in 1954.

Dr. Eisemann was a partner in the Statland Clinic in Overland Park, Kansas, for 50 years, until his retirement in 2004. After his retirement, he was a volunteer physician at the Health Partnership Clinic of Johnson County.

He held several faculty and leadership positions throughout his career, including serving as a past president and honorary member of the Menorah Medical Center medical staff, acting as a hematology consultant at the Kansas City Veterans Affairs Hospital for 40 years, and working as a clinical professor of medicine at Kansas University Medical Center. Dr. Eisemann was a founding member of the Jewish Heritage Foundation, an honorary member of the Menorah Legacy Foundation, and the first recipient of the foundation’s Legacy Award.

Dr. Eisemann is survived by his wife of 64 years, three sons, and eight grandchildren.

Source: The Kansas City Jewish Chronicle.

Steven Rosen, MD
Christiane Querfeld, MD, PhD

City of Hope Researchers Receive $7.5 Million Grant to Study Cutaneous Lymphoma

The National Cancer Institute (NCI) awarded $6.3 million to Steven Rosen, MD, and Christiane Querfeld, MD, PhD, researchers at City of Hope in Duarte, California who are developing new therapies for the treatment of cutaneous T cell lymphoma. The pair also received two individual grants from the Leukemia & Lymphoma Society, totaling $1.2 million over three years.

Dr. Querfeld is chief of dermatology and director of City of Hope’s Cutaneous Lymphoma Program. She will use her grants to support efforts to map the communication network among the disease’s cellular, molecular, and immunologic microenvironment and to conduct a clinical phase I/II trial evaluating immune checkpoint PD1/PD-L1 inhibitors in this setting.

Dr. Rosen, the Irell & Manella Cancer Center Director’s Distinguished Chair at City of Hope, will use the funding to build the foundational knowledge scientists need to develop targeted drug therapies for people with cutaneous T cell lymphoma.

Source: City of Hope press release, March 20, 2019.

Cigall Kadoch, PhD

Cigall Kadoch Wins 2019 Wachtel Cancer Research Prize

The American Association for the Advancement of Science and Science Translational Medicine presented its 2019 Martin and Rose Wachtel Cancer Research Award to Cigall Kadoch, PhD, an assistant professor of pediatric oncology at Dana-Farber Cancer Institute in Boston.

The prize is awarded annually to early-career investigators who have performed outstanding work in the field of cancer research.

Dr. Kadoch is codirector of the epigenomics program at the Broad Institute of Massachusetts Institute of Technology and Harvard University. She studies chromatin regulation, focusing on rare, molecularly well-defined cancers to understand how aberrant chromatin remodeling promotes a wide range of more common cancer types.

Source: Dana-Farber Cancer Institute press release, March 15, 2019.

Pat Basu, MD, MBA

Cancer Treatment Centers of America Names New President and CEO

Pat Basu, MD, MBA, was appointed president and CEO of Cancer Treatment Centers of America (CTCA), which includes the existing Comprehensive Cancer Care Network of CTCA hospitals and outpatient care centers, as well as new business ventures. He also will serve as a member of the CTCA National Board of Directors.

Dr. Basu has held leadership positions in corporate, government, private equity, and clinical organizations. He previously worked as a physician at the Stanford University Medical Center, then served as a White House fellow and senior advisor. Recently, he was a member of the Executive Leader Team at UnitedHealth Group and was senior vice president at Optum. He also served as president, chief operating officer, and chief medical officer for vRad, a large provider of radiology services.

Dr. Basu sees patients on a part-time basis in the Veterans Affairs hospital system and has held visiting faculty appointments at several universities.

Source: Cancer Treatment Centers of America press release, April 3, 2019.

Charles G. Mullighan, MD

St. Jude Selects Charles Mullighan as Cancer Center Deputy Director

The St. Jude Children’s Research Hospital Comprehensive Cancer Center in Memphis, Tennessee has appointed Charles G. Mullighan, MD, its new deputy director.

In this role, Dr. Mullighan will lead precision medicine, preclinical, and other strategic research initiatives for the center, with a focus on using integrated genomic and epigenomic approaches to understand and treat malignancies.

“The last decade has wrought enormous advances in our understanding of the genetic basis of leukemia and other childhood cancers,” Dr. Mullighan said in a press release announcing his appointment. “The Cancer Center is poised to have a key role in translating this knowledge into better diagnostic and therapeutic approaches to improve outcomes for children with cancer locally and globally.”

Having joined the St. Jude department of pathology faculty in 2008, Dr. Mullighan has worked in several capacities at the organization. He currently serves as coleader of the Cancer Center’s Hematological Malignancies Program, holds the William E. Evans Endowed Chair, and serves as medical director of the St. Jude Biorepository. In 2016, he was awarded the American Society of Hematology’s (ASH’s) William Dameshek Prize.

Source: St. Jude Children’s Research Hospital press release, April 25, 2019.

New NAS Member Class Includes Historic Number of Women

The National Academy of Sciences (NAS) has elected 100 new members and 25 foreign associates, bringing the number of active members to 2,347 and foreign associates to 487. This includes a record number of women – 40% – as well as two hematologists and ASH members:

  • Nancy A. Speck, PhD, investigator at the Abramson Family Cancer Research Institute and professor in the department of cell and developmental biology at the University of Pennsylvania School of Medicine
  • Timothy J. Ley, MD, Lewis T. and Rosalind B. Apple Chair in Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis, Missouri

NAS members are selected in recognition of their ongoing achievements in original research.

Source: National Academy of Sciences press release, April 30, 2019.